Clinical Trials Logo

Cerebral Infarction clinical trials

View clinical trials related to Cerebral Infarction.

Filter by:

NCT ID: NCT00386191 Completed - Cerebral Infarction Clinical Trials

Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment

Start date: September 2006
Phase: Phase 4
Study type: Interventional

The primary objective is to compare the safety of clopidogrel 50mg and 75mg in cerebral infarction with respect to incidence of bleeding adverse events.

NCT ID: NCT00376207 Completed - Cerebral Infarction Clinical Trials

Physical Activity After Stroke: How Does it Effect Chronical Inflammation and Insulin Sensitivity

Start date: January 2006
Phase: N/A
Study type: Interventional

Decreased insulin sensitivity is and independent risk factor for stroke despite glycemic control. It is known that physical exercise increases insulin sensitivity in healthy subjects. Wether stroke patients can increase insulin sensitivity via physical exercise is not known. Chronic low-grade inflammation is associated with an increased risk of stroke. Physical exercise has shown to increase IL-6 directly after exercise in untrained subjects. When fitness is increased in each subject then the peak IL-6 concentration after exercise decreases and so does the basal level of IL-6. It is not known whether stroke patients can increase physical activity level to a degree where chronic inflammation are decreased. This study is designed to evaluate if physical exercise after stroke will increases insulin sensitivity and reduce low-grade chronic inflammation. Stroke patients have been randomized to intervention with physical exercise or control in the ExStroke pilot trial and followed for 2 years. Using the study population from the ExStroke pilot trail blood samples will be obtained at the last control. Insulin sensitivity can be measured from fasting glucose and insulin using the Homeostasis Model Assessment (HOMA). Interleukin-6, TNF-alfa and CRP is measured to estimate chronic inflammation.

NCT ID: NCT00351806 Completed - Cerebral Infarction Clinical Trials

AISTCM-Outcome Measurement of Acute Ischemic Stroke With Traditional Chinese Medicine

Start date: July 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether Traditional Chinese Medicine (TCM) is able to improve the outcome of acute ischemic stroke and to observe its safety.

NCT ID: NCT00343174 Completed - Acute Stroke Clinical Trials

Intravenous Ancrod for the Treatment of Acute Ischemic Stroke Within 6 Hours After Onset of Symptoms

Start date: n/a
Phase: Phase 3
Study type: Interventional

Treatment of acute stroke is still difficult and the only specific drug approved (rtPA) can only be administered if treatment starts within 3 hours after onset of symptoms. This results in a still too small number of patients treated with rtPA ( < 15% in best clinical care institutions ). Ancrod is a differently acting biological drug which has been used for a long time but not for acute stroke treatment. STAT was the first RCT of medium size to show a significant benefit/risk ration if treatment starts within 3 hours. ESTAT was designed closely related to STAT but with a longer 6 hours window and specifically extended inclusion/exclusion criteria to avoid secondary complications possibly related to a longer time window.

NCT ID: NCT00331890 Terminated - Acute Stroke Clinical Trials

ICTUS Study: International Citicoline Trial on Acute Stroke

ICTUS
Start date: October 2006
Phase: Phase 3
Study type: Interventional

Citicoline is a safe drug approved in some countries for the treatment of acute ischemic stroke. The drug has shown some evidence of efficacy in a pooled analysis, based on four clinical trials done in USA with oral citicoline.The purpose of the study is confirm the results obtained in the pooled analysis, that is, evidence of efficacy in the treatment of acute ischemic stroke

NCT ID: NCT00318071 Completed - Ischemic Stroke Clinical Trials

Multi MERCI (Mechanical Embolus Removal in Cerebral Ischemia [MERCI™])

Multi-MERCI
Start date: January 2004
Phase: N/A
Study type: Interventional

The primary objectives of the Multi MERCI trial were: - to evaluate the addition of the Merci L5 Retriever - additionally permit use of the Merci Retrieval System in the setting of persistent clot following IV t-PA treatment (use in the 0-8 hour window for patients ineligible for IV t-PA was also permitted)

NCT ID: NCT00306579 Completed - Ischemic Stroke Clinical Trials

Myocardial Damage In Patients With Cerebral Infarction

Start date: August 2003
Phase: N/A
Study type: Observational

Introduction For several years "ischemic" electrocardiographic (ECG) changes in the acute phase of ischemic stroke have been reported. Whether these ECG changes reflect true myocardial ischemia remains controversial. So far no study has assessed different markers of myocardial ischemia or necrosis in consecutive patients admitted to hospital with an acute ischemic stroke. Purpose The main purpose of this study is to determine the potential burden of reversible and irreversible myocardial ischemia in patients with an acute ischemic stroke. Patients and methods Serial blood samples for measuring troponin T, CK-MB and NT-proBNP are collected in 250 patients with evidence of an acute ischemic stroke admitted to the Department of Neurology at Odense University Hospital. In addition resting 12-lead ECG recordings will be obtained on a daily basis, and a 24-hour ST-segment ambulatory monitoring will be performed once within the first week of hospitalisation. Finally, myocardial perfusion patterns during rest will be evaluated by means of a myocardial perfusion scintigraphy in patients with an elevated troponin T level. Six months later control measurements of troponin T, CK-MB and NT-proBNP and a 12-lead ECG will be obtained. Expectations The study will contribute with original observations in patients with acute ischemic stroke considering the following issues: 1. The prevalence and characteristics of ECG changes suggestive of myocardial ischemia. 2. The prevalence of transient ST-segment changes on ambulatory monitoring. 3. The prevalence and degree of myocardial necrosis as judged from biochemical markers. 4. The prevalence of reversible and irreversible perfusion defects on myocardial scintigraphy. 5. The prevalence, size and patterns of NT-proBNP. 6. Whether there is a change in ECG and biochemical markers over a 6-month follow-up period. The results may have clinical implications regarding early and late treatment as well as clinical follow-up of patients recovering from an episode of acute ischemic stroke.

NCT ID: NCT00300196 Terminated - Stroke Clinical Trials

ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke

Start date: March 2006
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine whether a brief intravenous infusion of ancrod started within 6 hours of stroke onset improves functional outcome at 3 months.

NCT ID: NCT00272454 Completed - Cerebral Infarction Clinical Trials

Cilostazol in Acute Ischemic Stroke Treatment (CAIST)

Start date: January 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to study efficacy and safety of cilostazol use in patients with acute ischemic stroke.

NCT ID: NCT00262691 Recruiting - Healthy Clinical Trials

Investigation of Genetic Risk of Cardiovascular Disease in Prospective Cohort Study

Start date: May 2005
Phase: N/A
Study type: Observational

Cardiovascular disease is a complex multifactorial and polygenic disorder that is thought to result from an interaction between a person's genetic make up and various environmental factors. Although many studies have revealed that several genetic variants increase the risk of cardiovascular disease, the results of these studies remain controversial. The purpose of this study is to identify polymorphisms that confer susceptibility to cardiovascular disease and to clarify the adequacy of reported susceptibility gene polymorphisms. To complete this purpose, we will prospectively study over 5,000 local residents in whom relationship between these polymorphisms and occurrence of cardiovascular disease over 5 years.